Howrey LLP - United Kingdom - Cambridge Antibody Technology V Abbott Biotechnology Limited (25/07/2005) from Mondaq
Howrey LLP - United Kingdom - Cambridge Antibody Technology V Abbott Biotechnology Limited (25/07/2005) from Mondaq

United Kingdom: Cambridge Antibody Technology V Abbott Biotechnology Limited
Free Weekly Newsletters
Would you like to be kept informed about similar articles? >Signup<



Further information
Give Firm your Feedback

Sign up for a free News Alert

Information contributed by Howrey LLP
View all Articles by this Firm

View summary of all information contributed

View Firm's Website

General links
Email a colleague with a synopsis and link to this article

Printer-friendly version of this page

Become a contributor


Legal Jobs


View Other Articles Classified By:
Intellectual Property

Pharmaceutical, Healthcare & Life Sciences

Biotechnology, Life Sciences & Healthcare

Licensing & Syndication

Patent

Trade Secrets

Arbitration & Dispute Resolution

Commercial

Healthcare/ Medical

Life Sciences & Biotechnology

Patents

25 July 2005
Article by Calum Smyth
In one of the year’s most valuable contract claims to come before the UK Patents Court, the CAT v Abbott dispute demonstrates the importance of properly understanding both the extent of existing IP rights and the nature of the protected technology, when drafting commercial agreements in technically complex fields.

Under two collaboration agreements (the "Agreements") Abbott was licensed to use CAT's patented technology in order to develop an antibody to a protein known as TNFa - a protein thought to play a large part in rheumatoid arthritis. The case concerned a dispute over the amount of royalties payable in relation to Abbott's sales of HUMIRA, a blockbuster biologic rheumatoid arthritis drug that utilises the TNFa antibody....


Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Biotech News

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech